Related Experiment Video

Updated: Jul 15, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Treating hepatitis C virus in HIV patients: are side effects a real obstacle?

Francesca Gatti1, Paola Nasta, Alessandro Matti

  • 1Department of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy. francesca_gatti1@virgilio.it

AIDS Reviews
|May 4, 2007
PubMed

Insights

Hepatitis C virus (HCV) complications are a major cause of death in HIV patients. This review updates clinicians on managing side effects from pegylated interferon and ribavirin treatment in coinfected individuals.

Area of Science:

  • Hepatology and Infectious Diseases
  • Viral Hepatitis and HIV Coinfection Management

Background:

  • Hepatitis C virus (HCV)-related complications significantly contribute to morbidity and mortality in individuals with human immunodeficiency virus (HIV).
  • Current guidelines recommend evaluating and treating all HIV/HCV-coinfected patients with pegylated interferon and ribavirin.
  • Effective management of treatment side effects is crucial to prevent early discontinuation, especially in HIV patients where adverse events can be more severe.

Purpose of the Study:

  • To provide clinicians with an updated review on the management of pegylated interferon and ribavirin side effects in HCV/HIV-coinfected patients.
  • To summarize the latest literature on the underlying mechanisms, incidence, and clinical advice for managing these adverse events.

Main Methods:

  • Literature review of recent and relevant scientific publications.
  • Synthesis of information on the mechanisms, incidence, and management strategies for treatment side effects.

Main Results:

  • Pegylated interferon and ribavirin treatment for HCV in HIV-coinfected patients can lead to significant side effects.
  • Understanding the mechanisms and incidence of these side effects is key to effective management.
  • Proactive management strategies are essential to ensure treatment adherence and minimize early discontinuations.

Conclusions:

  • Clinicians require up-to-date information to effectively manage pegylated interferon and ribavirin side effects in HIV/HCV-coinfected patients.
  • Optimizing treatment outcomes necessitates a thorough understanding and proactive approach to managing adverse events.
  • This review serves as a resource for clinicians to improve patient care and treatment success rates.

More Related Videos

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...